Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Jaryga

Podiatrist Ft Worth, TX Doctor of Podiatric Medicine

NPI 1265481600 CMS profile 57644

7100 Oakmont Blvd, Suite 208, Ft Worth, TX 76132

Open in the dashboard

General payments

$174,747

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Jaryga of Ft Worth, TX is reported in the CMS Open Payments database as having received $174,747 across 280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,762 28
2024 General $34,340 47
2023 General $44,473 55
2022 General $39,469 64
2021 General $25,478 28
2020 General $11,383 21
2019 General $14,841 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Jaryga
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Gregory Jaryga were reported at $4,762. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Gregory Jaryga Podiatrist median Middle half National median
2019 $14,841 $196 $72–$601 $163
2020 $11,383 $118 $38–$335 $114
2021 $25,478 $169 $57–$573 $132
2022 $39,469 $220 $74–$782 $149
2023 $44,473 $208 $71–$635 $160
2024 $34,340 $237 $87–$681 $164
2025 $4,762 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orthofix Medical, Inc. $144,324 162 payments
  2. AMDT Holdings, Inc. $18,763 5 payments
  3. Arthrex, Inc. $5,470 14 payments
  4. Anika Therapeutics, Inc. $1,530 24 payments
  5. Pylant Medical $1,432 3 payments
  6. Stryker Corporation $1,406 23 payments
  7. Arthrosurface Incorporated $610 13 payments
  8. Wright Medical Technology, Inc. $336 9 payments
  9. MedShape, Inc. $157 2 payments
  10. Nevro Corp. $107 1 payment
  11. Other $613 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $136,220 34 payments
  2. Royalty or License $25,237 38 payments
  3. Food and Beverage $6,899 172 payments
  4. Travel and Lodging $3,901 32 payments
  5. Education $2,490 4 payments
Products named General payments · program years 2019–2025
  1. TrueLok $55,520 134 payments
  2. JUNIORTHO PLATING SYSTEM $49,579 11 payments
  3. ANKLE HINDFOOT NAILING SYSTEM $21,463 4 payments
  4. Contours PHP $5,735 2 payments
  5. M2 Multiplanar MiniRail $4,559 3 payments
  6. PORD Device $4,185 2 payments
  7. Pennig Minifixator $4,069 2 payments
  8. OSCAR3 $4,069 2 payments
  9. Gotfried PC.C.P. $4,030 1 payment
  10. Guided Growth System $4,030 1 payment
  11. Other $73,069 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

910

Median for Podiatry: 160

Drug cost

$9,618

Median for Podiatry: $2,368

Branded share of claims

21.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Etodolac Generic 67 $1,879
Celecoxib Generic 88 $1,248
Gabapentin Generic 133 $1,060
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 31 $819
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 74 $587
Methylprednisolone Generic 69 $575
Pregabalin Generic 15 $414
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $399
Ciprofloxacin Hcl Generic 44 $356
Meloxicam Generic 117 $354

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$53,115

Medicare's payments for the services billed

Medicare patients

256

Average age 75

Services billed

861

133 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 37%
Ischemic heart disease 32%
Chronic kidney disease 29%
Depression 24%
Atrial fibrillation 23%
Cancer 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record